Velagliflozin, a once-daily, liquid, oral SGLT2 inhibitor, is effective as a stand-alone therapy for feline diabetes mellitus: the SENSATION study

• DOI: 10.2460/javma.24.03.0174
• Publication Date: 2024-08-14T16:02:12Z
• Authors: Ellen N. Behrend; Cynthia R. Ward; Victor Chukwu; Audrey K. Cook; Carla Kroh; Patty Lathan; Jacky May; Thomas Schermerhorn; J. Catharine Scot...; Rebecca Voth
• Keywords: Ketonuria; Polyuria; Fructosamine; Polydipsia; Diabetic ketoacidosis

Abstract OBJECTIVE To investigate safety and effectiveness of velagliflozin oral solution as sole therapy in naïve previously insulin-treated diabetic cats. ANIMALS 252 client-owned cats receiving ≥ 2 doses velagliflozin; 214 (85%) diabetics 38 (15%) diabetics. PROCEDURES Prospective, baseline-controlled, open-label clinical field trial. Cats received orally, once daily. Physical examinations blood collections were performed days 0, 3, 7, 30, 60, 120, 180. RESULTS Data are median (range). Screening glucose (BG) was 436 mg/dL (272 to 676 mg/dL). On 180, single BG after 153 (62 480 mg/dL), 134 (64 414 128 (55 461 125 (77 384 respectively. fructosamine 538 µmol/L (375 794 µmol/L). the same recheck days, 310 (204 609 µmol/L), 286 (175 531 269 (189 575 263 (203 620 At day 81% 158 remaining had and/or within reference ranges; 88.6% (124 140) 87.7% (121 138) showed improvement polyuria polydipsia, Ketonuria developed 35 (13.9%), including 18 (7.1%) that ketoacidosis. Ketoacidosis less common (11 [5.1%]) compared (7 [18.4%]). ketoacidosis diagnosis, 14 (77.8%) euglycemic (ie, < 250 Most episodes ketosis or (30 [85.7%]) occurred first treatment. Insulin-treated likely complete No hypoglycemia occurred. CLINICAL RELEVANCE Velagliflozin improved glycemic parameters signs provides an alternative insulin a stand-alone treatment